TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18329013

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 microg/m(3))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (100 microg/m(3))
Number of subjects: 16
Study: 16350715

Group type: EXPERIMENTAL
Intervention: T allele of Taq I VDR gene
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Genotypes: aa, bb, TT of VDR gene
Number of subjects: 206
Study: 11868798

Group type: EXPERIMENTAL
Intervention: AmB and oral spironolactone 100 mg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: AmB alone
Number of subjects: 26
Study: 10594411

Group type: EXPERIMENTAL
Intervention: Laryngoscopy and tracheal intubation (n = 18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laryngeal mask airway insertion (n = 16)
Number of subjects: 34
Study: 7781578

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation with EMLA cream
Number of subjects: 0
Study: 2083605

Group type: EXPERIMENTAL
Intervention: Cimetidine plus clemastine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus clemastine
Number of subjects: 20
Study: 7418570

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (2000 rad Co60)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Radical Co60 therapy + Methotrexate + 5-Fluorouracil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Co60 therapy alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Surgery without previous radiotherapy
Number of subjects: 66
Study: 31750786

Group type: COMPARATOR
Intervention: Multimodal treatment (3 times a week for 6 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Targeted intervention (6 weeks) based on subgroup characteristics
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'weak and pronated foot' subgroup
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'weak and tight' subgroup
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'strong' subgroup
Number of subjects: 61
Study: 31182139

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril) added to standard of care
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard of care (placebo)
Number of subjects: 280
Study: 28917232

Group type: EXPERIMENTAL
Intervention: CFMO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CFSO
Number of subjects: 12
Study: 27276835

Group type: EXPERIMENTAL
Intervention: Medical Nutritional Therapy (MNT) with Self Blood Glucose Monitoring (SBGM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 23551127

Group type: EXPERIMENTAL
Intervention: Routine early tirofiban treatment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Deferred provisional tirofiban treatment
Number of subjects: 286
Study: 21238859

Group type: EXPERIMENTAL
Intervention: King County restaurants (intervention group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control locations (non-intervention group)
Number of subjects: 14
Study: 19130293

Group type: EXPERIMENTAL
Intervention: SSKI (Saturated Solution Potassium Iodide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17117398

Group type: EXPERIMENTAL
Intervention: NeuroPsychological Training (TNP) plus cholinesterase inhibitors
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors alone
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study: 14757591

Group type: EXPERIMENTAL
Intervention: Combined psychotherapy (8 sessions of cognitive behavior therapy) plus pharmacotherapy (citalopram)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 109
Study: 11158406

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rHuEpo) therapy for 3 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rHuEpo) therapy for 1 year
Number of subjects: 26
Study: 9547958

Group type: EXPERIMENTAL
Intervention: Simulators (normal participants feigning memory impairment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coin-in-the-hand test with autobiographical interview
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal participants (performing honestly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Memory-impaired participants
Number of subjects: 40
Study: 7519005

Group type: EXPERIMENTAL
Intervention: Selegiline 60 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3219752

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxacillin plus gentamicin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 30081055

Group type: EXPERIMENTAL
Intervention: 24 IU of oxytocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 28387017

Group type: EXPERIMENTAL
Intervention: Massage Therapy in Multisensory Environment (MT in MSE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multisensory Environment (MSE) alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT) alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 42
Study: 25707380

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11
Study: 23496822

Group type: EXPERIMENTAL
Intervention: BMR with BET (behaviour-oriented)
Number of subjects: 214

Group type: COMPARATOR
Intervention: BMR with SET (function-oriented)
Number of subjects: 214
Study: 20852958

Group type: EXPERIMENTAL
Intervention: Alprazolam (anxiolytic medication)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no medication administered for anxiety reduction)
Number of subjects: 60
Study: 18635724

Group type: EXPERIMENTAL
Intervention: 17 mg THC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 13 mg THC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 13 mg and 17 mg THC
Number of subjects: 14
Study: 17065274

Group type: EXPERIMENTAL
Intervention: Single 2-hour infusion of cetuximab at doses of 50, 100, 250, 400, or 500 mg/m2 followed by weekly 1-hour infusions of cetuximab at a fixed dose of 250 mg/m2
Number of subjects: 40
Study: 12921449

Group type: EXPERIMENTAL
Intervention: Enfamil AR
Number of subjects: 104
Study: 10752747

Group type: EXPERIMENTAL
Intervention: Fibroblasts from patients with hypertrophic burn scars (HBSs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (unstimulated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (serum stimulated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (serum and interferon‐gamma stimulated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control fibroblasts (unstimulated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control fibroblasts (serum stimulated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control fibroblasts (serum and interferon‐gamma stimulated)
Number of subjects: 0
Study: 9558629

Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with industrial noise-induced hearing loss.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with presbycusis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with hearing impairment caused by gentamycin.
Number of subjects: 0
Study: 1604987

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2437086

Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A: 36 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CT alone (arm B: 44 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A) and CT alone (arm B)
Number of subjects: 80
Study: 29354928

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with HAART (zidovudine, lamivudine, nevirapine, efavirenzone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simple HAART
Number of subjects: 100
Study: 26658446

Group type: EXPERIMENTAL
Intervention: Calls made by paramedics to physician-investigators
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Reasons for screen failure
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Barriers for phone informed consent
Number of subjects: 4458
Study: 23657879

Group type: EXPERIMENTAL
Intervention: Intraarticular fibrinogen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 200
Study: 23780378

Group type: EXPERIMENTAL
Intervention: ILP (Interstitial laser photocoagulation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 44
Study: 20625263

Group type: EXPERIMENTAL
Intervention: Zidovudine plus standard-dose lopinavir/ritonavir (LPV/r) 300 mg zidovudine and 400/100 mg LPV/r twice daily from 28 weeks' gestation until delivery
Number of subjects: 38
Study: 18974537

Group type: EXPERIMENTAL
Intervention: Group A: necrotic coronal pulp removal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B: necrotic coronal and accessible radicular pulp removal
Number of subjects: 60
Study: 19478654

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study: 15731312

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8%) administered once a day for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (gel without vaginal progesterone) administered once a day for 5 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8%)
Number of subjects: 50
Study: 11568372

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Midazolam and morphine infusion (10 microg/kg/h)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo and morphine infusion (10 microg/kg/h)
Number of subjects: 33
Study: 9643277

Group type: EXPERIMENTAL
Intervention: Enalapril treatment initiated intravenously within 24 hours after acute myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 0
Study: 7888290

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 micrograms twice daily for 3.5 days
Number of subjects: 0
Study: 17171886

Group type: EXPERIMENTAL
Intervention: HD-HES (hydroxyethyl starch solution, ratio 1:1, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HD-RL (Ringer's lactate, ratio 2.5:1, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study: 30535100

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 604

Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy
Number of subjects: 604
Study: 27840299

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) administered over the lumbar paraspinal muscles for 60 minutes per day, three times per week, for 4 consecutive weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received muscle stimulation at the minimal sensory threshold intensity
Number of subjects: 30
Study: 26004718

Group type: EXPERIMENTAL
Intervention: Pepsil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safoof-e-katira
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study: 24290290

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Percent of body fat
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Lung function
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Asthma severity/control
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Sensitization to cockroach
Number of subjects: 678
Study: 22428490

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at 50 microg/min
Number of subjects: 117

Group type: COMPARATOR
Intervention: Phenylephrine infusion at 100 microg/min
Number of subjects: 117
Study: 19438480

Group type: EXPERIMENTAL
Intervention: Number needed to treat (NNT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 0
Study: 17606655

Group type: EXPERIMENTAL
Intervention: Columbia Classification Algorithm for Suicide Assessment (C-CASA)
Number of subjects: 427
Study: 14971967

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (ULT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham-ultrasound (CON)
Number of subjects: 14
Study: 11180314

Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trials
Number of subjects: 0
Study: 9040811

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (sterile physiologic saline)
Number of subjects: 45
Study: 7946890

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 3068050

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of epinephrine plus polidocanol (group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medical treatment (group B)
Number of subjects: 72
Study: 28836373

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice plus Smartphone Application Group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lifestyle Advice Only Group
Number of subjects: 162
Study: 27879654

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study: 24963731

Group type: COMPARATOR
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: 5 minutes of Brief Advice (BA)
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: 20 minutes of Brief Lifestyle Counseling (BLC)
Number of subjects: 1497
Study: 22901498

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 555

Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt
Number of subjects: 555
Study: 19785618

Group type: EXPERIMENTAL
Intervention: 0.2% SCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% SCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% SCG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (no SCG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SCG (all concentrations)
Number of subjects: 60
Study: 18285316

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg + saquinavir 1000 mg twice daily (arm A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg + saquinavir 600 mg twice daily (arm B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 266/66 mg + saquinavir 1000 mg twice daily (arm C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 266/66 mg + saquinavir 600 mg twice daily (arm D)
Number of subjects: 48
Study: 15807813

Group type: EXPERIMENTAL
Intervention: Zinc oxide adhesive
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydrocolloid adhesive
Number of subjects: 11
Study: 11956422

Group type: EXPERIMENTAL
Intervention: 4.7Fr multi-length stent
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 7Fr multi-length stent
Number of subjects: 97

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 97
Study: 10215657

Group type: EXPERIMENTAL
Intervention: W/O/W of small IPSO microdroplets (30 micrometers in diameter) containing 60 mg of epirubicin (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: W/O/W of large IPSO microdroplets (70 micrometers) containing 60 mg of epirubicin (group B)
Number of subjects: 32
Study: 7705673

Group type: EXPERIMENTAL
Intervention: rhu IL‐3 administered after chemotherapy (250 and 500 micrograms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhu IL‐3 administered before chemotherapy (50 micrograms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhu IL‐3 (50 micrograms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhu IL‐3 (250 and 500 micrograms)
Number of subjects: 18
Study: 2568661

Group type: EXPERIMENTAL
Intervention: CM6912 (ethyl loflazepate) 1 mg twice daily (CM-1 group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CM6912 (ethyl loflazepate) 2 mg once daily (CM-2 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (DZP) 2 mg three times daily
Number of subjects: 0
Study: 781206

Group type: EXPERIMENTAL
Intervention: Exchange transfusion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fresh frozen plasma or conventional supportive care
Number of subjects: 101
Study: 30227936

Group type: EXPERIMENTAL
Intervention: Structured counseling with an emphasis on LARC by a family planning specialist
Number of subjects: 121

Group type: COMPARATOR
Intervention: Routine postpartum care
Number of subjects: 121
Study: 27330023

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg twice daily for four days then 4 mg twice daily for three days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 41
Study: 24585205

Group type: EXPERIMENTAL
Intervention: Joint crisis plans
Number of subjects: 41
Study: 22453774

Group type: EXPERIMENTAL
Intervention: Cough Aid
Number of subjects: 74
Study: 21078804

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Peripheral blood-derived stem cells (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard therapy alone (group C)
Number of subjects: 15
Study: 18507748

Group type: EXPERIMENTAL
Intervention: Autologous red blood cells (RBCs) derived from umbilical cord blood (UCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic transfusions
Number of subjects: 0
Study: 15801015

Group type: EXPERIMENTAL
Intervention: Prasterone 200 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12562577

Group type: EXPERIMENTAL
Intervention: Olanzapine, 7.5 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Haloperidol, 2.5 mg/day
Number of subjects: 24
Study: 11359749

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 227

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 227
Study: 9103735

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (attention, information, brief relaxation instructions)
Number of subjects: 61
Study: 8466259

Group type: EXPERIMENTAL
Intervention: Intravenous glucagon (200 micrograms/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intragastric medium chain triglyceride (MCT) (5 ml/kg)
Number of subjects: 23
Study: 3709730

Group type: EXPERIMENTAL
Intervention: Soft gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hard gum
Number of subjects: 10
Study: 31117092

Group type: EXPERIMENTAL
Intervention: Herniamesh mesh
Number of subjects: 232

Group type: COMPARATOR
Intervention: Biological graft
Number of subjects: 232
Study: 29378708

Group type: EXPERIMENTAL
Intervention: Plazomicin 10 mg/kg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Plazomicin 15 mg/kg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Levofloxacin 750 mg
Number of subjects: 145
Study: 27310327

Group type: EXPERIMENTAL
Intervention: ASP2409 (0.001 to 3.0 mg/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ASP2409 (0.01 to 3.0 mg/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25423041

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Routine diagnostic algorithm (sputum microscopy and limited culture)
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Routine diagnostic algorithm
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF among HIV-infected participants
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Xpert MTB/RIF vs Routine diagnosis
Number of subjects: 1985
Study: 21715138

Group type: EXPERIMENTAL
Intervention: Low tidal volume mechanical ventilation (V(T), 6 mL/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional tidal volume mechanical ventilation (V(T), 10 mL/kg)
Number of subjects: 150
Study: 19605504

Group type: EXPERIMENTAL
Intervention: Capecitabine with Irinotecan (XI)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Capecitabine with Cisplatin (XP)
Number of subjects: 118
Study: 18495607

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 10 min before operation
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 5 min before operation
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg 1 min before operation
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg 10 min before operation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg (control group)
Number of subjects: 175
Study: 15677599

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 9260

Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 9260

Group type: COMPARATOR
Intervention: Switching from valproic acid to divalproex
Number of subjects: 9260